Pyrithyldione[1] (Presidon, Persedon) is a psychoactive drug invented in 1949.[2]
An improved method of manufacture was patented by Roche in 1959.[3] It was used as a hypnotic or sedative and presumed to be less toxic than barbiturates.[4] Today, this substance is no longer used. Agranulocytosis was sometimes reported as adverse effect.[5][6] Pyrithyldione is also a CYP2D6 inducer but is not as potent as glutethimide.[7] In studies, it increased the O-demethylation of codeine by 20%.
^US Patent 2090068 - 2,4-Dioxo-3,3-Dialkyl-Tetrahydropyridines and Process for the Manufacture of Same.
^Becker EL, Fabing HD, Hawkins JR (April 1949). "Presidon; a new sedative-hypnotic". Christ Hospital Medical Bulletin. 2 (4): 80–4. PMID18144514.
^US patent 3019230, Hinderling R, Lutz AH, Schnider O, "Method for the preparation of 2,4-dioxo-tetrahydropyridines", issued 1962-01-30, assigned to Hoffmann-La Roche
^Ibáñez L, Ballarín E, Pérez E, Vidal X, Capellà D, Laporte JR (January 2000). "Agranulocytosis induced by pyrithyldione, a sedative hypnotic drug". European Journal of Clinical Pharmacology. 55 (10): 761–4. doi:10.1007/s002280050011. PMID10663456. S2CID25595314.
^Covner AH, Halpern SL (January 1950). "Fatal agranulocytosis following therapy with presidon (3,3-diethyl-2,4-dioxotetrahydropyridine) a new sedative hypnotic agent". The New England Journal of Medicine. 242 (2): 49–52. doi:10.1056/NEJM195001122420203. PMID15399031.